Clinical trial
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including PegIFNa-2a and Ribavirin in HCV Genotype 1 Infected Subjects Who Failed Previous Standard Therapy
NCT00980330 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including PegIFNa-2a and Ribavirin in HCV Genotype 1 Infected Subjects Who Failed Previous Standard Therapy
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- August 31, 2011
- Enrollment
- 463 (actual)
- Sites
- 78
Conditions
As the registry lists them; a condition with its own page is linked.